AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR TREATMENT-REFRACTORY RELAPSING MULTIPLE SCLEROSIS: POSITION STATEMENT FROM THE AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION.Biol Blood Marrow Transplant.(2019).
Autologous Transplantation for Male Germ Cell Tumors: Improved Outcomes over 3 decades.Biol Blood Marrow Transplant.(2019).
The concentration of total nucleated cells in harvested bone marrow for transplantation has decreased over time.Biol Blood Marrow Transplant.(2019).
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.Biol Blood Marrow Transplant.(2019).
Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia over 45 years of age.Cancer.(2019).
Inferior Outcomes with Cyclosporine and Mycophenolate mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant.(2019).
Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation.Br J Haematol.(2019).
Survival Outcomes of Allogeneic Hematopoietic Cell Transplants with EBV positive or EBV negative Post Transplant Lymphoproliferative Disorder (PTLD), A CIBMTR Study.Transpl Infect Dise13145.(2019).
Transgender individuals represent an overlooked population amongst stem cell donors.Bone Marrow Transplant.(2019).
Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transpl.Biol Blood Marrow Transplant.(2018).
Comparative analysis of calcineurin-inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of Graft-versus-Host Disease after reduced intensity conditioning allogeneic transplantation.Biol Blood Marrow Transplant.(2018).
Comparative Outcomes of Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Acute Myeloid Leukemia with Prior Solid Tumor: a report from the ALWP of the EBMT.Am J Hematol.(2018).
Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party Eu.Am J Hematol.(2018).
Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.Biol Blood Marrow Transplant.(2018).
Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.Biol Blood Marrow Transplant.(2018).
Revised-International Staging System (R-ISS) is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma (MM)..Biol Blood Marrow Transplant.(2018).
Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.Br J Haematol.(2016).
An Analysis of the Effect of Race, Socioeconomic Status and Center Size on Unrelated NMDP Donor Outcomes: Donor Toxicities are More Common at Low Volume Bone Marrow Collection Centers.Biol Blood Marrow Transplant.(2015).
Randomized, Double Blind, Study of the safety and Immunogenicity of Standard-Dose Trivalent Inactivated Influenza Vaccine versus High-Dose Trivalent Inactivated Influenza Vaccine in Adult Hematopoietic Stem Cell Transplant Patients.Biol Blood Marrow Transplant.(2015).
Systematic nutritional support in allogeneic HSCT recipients.Biol Blood Marrow Transplant.(2015).
Low CD34 Dose is Associated with Poor Survival after Reduced Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome.Biol Blood Marrow Transplant.(2014).
Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation.Biol Blood Marrow Transplant.(2014).